|
1
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spirtas R, Heineman EF, Bernstein L, Beebe
GW, Keehn RJ, Stark A, Harlow BL and Benichou J: Malignant
mesothelioma: Attributable risk of asbestos exposure. Occup Environ
Med. 51:804–811. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robinson BM: Malignant pleural
mesothelioma: An epidemiological perspective. Ann Cardiothorac
Surg. 1:491–496. 2012.PubMed/NCBI
|
|
4
|
Flores RM, Riedel E, Donington JS, Alago
W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M and
Pass HI: Frequency of use and predictors of cancer-directed surgery
in the management of malignant pleural mesothelioma in a
community-based (Surveillance, Epidemiology, and End Results
[SEER]) population. J Thorac Oncol. 5:1649–1654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sekido Y, Pass HI, Bader S, Mew DJ,
Christman MF, Gazdar AF and Minna JD: Neurofibromatosis type 2
(NF2) gene is somatically mutated in mesothelioma but not in lung
cancer. Cancer Res. 55:1227–1231. 1995.PubMed/NCBI
|
|
6
|
Toyooka S, Carbone M, Toyooka KO,
Bocchetta M, Shivapurkar N, Minna JD and Gazdar AF: Progressive
aberrant methylation of the RASSF1A gene in simian virus 40
infected human mesothelial cells. Oncogene. 21:4340–4344. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi N, Toyooka S, Yanai H, Soh J,
Fujimoto N, Yamamoto H, Ichihara S, Kimura K, Ichimura K, Sano Y,
et al: Frequent p16 inactivation by homozygous deletion or
methylation is associated with a poor prognosis in Japanese
patients with pleural mesothelioma. Lung Cancer. 62:120–125. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kubo T, Toyooka S, Tsukuda K, Sakaguchi M,
Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, et al:
Epigenetic silencing of microRNA-34b/c plays an important role in
the pathogenesis of malignant pleural mesothelioma. Clin Cancer
Res. 17:4965–4974. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gazdar AF, Girard L, Lockwood WW, Lam WL
and Minna JD: Lung cancer cell lines as tools for biomedical
discovery and research. J Natl Cancer Inst. 102:1310–1321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su Z, Dias-Santagata D, Duke M, Hutchinson
K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL,
Iafrate AJ and Pao W: A platform for rapid detection of multiple
oncogenic mutations with relevance to targeted therapy in
non-small-cell lung cancer. J Mol Diagn. 13:74–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soh J, Okumura N, Lockwood WW, Yamamoto H,
Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et
al: Oncogene mutations, copy number gains and mutant allele
specific imbalance (MASI) frequently occur together in tumor cells.
PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sato A, Torii I, Tao LH, Song M, Kondo N,
Yoshikawa Y, Hashimoto-Tamaoki T, Hasegawa S, Nakano T and
Tsujimura T: Establishment of a cell line from a Japanese patient
useful for generating an in vivo model of malignant pleural
mesothelioma. Cancer Sci. 102:648–655. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shien K, Ueno T, Tsukuda K, Soh J, Suda K,
Kubo T, Furukawa M, Muraoka T, Maki Y, Tanaka N, et al: Knockdown
of the epidermal growth factor receptor gene to investigate its
therapeutic potential for the treatment of non-small-cell lung
cancers. Clin Lung Cancer. 13:488–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X and Chang A: Molecular predictors
of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int
J Med Sci. 5:209–217. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taniguchi T, Karnan S, Fukui T, Yokoyama
T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, et al:
Genomic profiling of malignant pleural mesothelioma with
array-based comparative genomic hybridization shows frequent
non-random chromosomal alteration regions including JUN
amplification on 1p32. Cancer Sci. 98:438–446. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Usami N, Fukui T, Kondo M, Taniguchi T,
Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y and
Hida T: Establishment and characterization of four malignant
pleural mesothelioma cell lines from Japanese patients. Cancer Sci.
97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prins JB, Williamson KA, Kamp MM, Van
Hezik EJ, Van der Kwast TH, Hagemeijer A and Versnel MA: The gene
for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is
preferentially deleted in malignant mesothelioma. Int J Cancer.
75:649–653. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee AY, Raz DJ, He B and Jablons DM:
Update on the molecular biology of malignant mesothelioma. Cancer.
109:1454–1461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007.
View Article : Google Scholar : PubMed/NCBI
|
